Avandia, SmithKline Beecham's oral diabetes drug, which was approved last May, has passed the 1 million retail prescription mark in its first seven months on the market and is leading the thiazolidinedione class. That class includes Takeda's Actos and Warner-Lambert's Rezulin. The company said it is seeking expanded indications in 2000 for the drug, which was approved for the treatment of type 2 diabetes as both monotherapy and in combination with metformin as an adjunct to diet and exercise.
COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group